DE69635346T4 - Von kloniertem, vitamin-d bindenden protein abgeleitete makrophagen-aktivierende faktoren - Google Patents

Von kloniertem, vitamin-d bindenden protein abgeleitete makrophagen-aktivierende faktoren Download PDF

Info

Publication number
DE69635346T4
DE69635346T4 DE69635346T DE69635346T DE69635346T4 DE 69635346 T4 DE69635346 T4 DE 69635346T4 DE 69635346 T DE69635346 T DE 69635346T DE 69635346 T DE69635346 T DE 69635346T DE 69635346 T4 DE69635346 T4 DE 69635346T4
Authority
DE
Germany
Prior art keywords
protein
cloned
cells
domain iii
gcmaf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69635346T
Other languages
German (de)
English (en)
Other versions
DE69635346D1 (de
DE69635346T2 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/478,121 external-priority patent/US5620846A/en
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69635346T2 publication Critical patent/DE69635346T2/de
Publication of DE69635346T4 publication Critical patent/DE69635346T4/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01049—Alpha-N-acetylgalactosaminidase (3.2.1.49)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
DE69635346T 1995-06-07 1996-06-05 Von kloniertem, vitamin-d bindenden protein abgeleitete makrophagen-aktivierende faktoren Expired - Lifetime DE69635346T4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/478,121 US5620846A (en) 1995-06-07 1995-06-07 Diagnostic and prognostic indices for cancer and aids
US478121 1995-06-07
US618485 1996-03-19
US08/618,485 US6410269B1 (en) 1995-06-07 1996-03-19 Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis
PCT/US1996/008867 WO1996040903A1 (en) 1995-06-07 1996-06-05 Macrophage activating factors derived from cloned vitamin d binding protein

Publications (2)

Publication Number Publication Date
DE69635346T2 DE69635346T2 (de) 2006-07-27
DE69635346T4 true DE69635346T4 (de) 2007-11-08

Family

ID=27045792

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69635346T Expired - Lifetime DE69635346T4 (de) 1995-06-07 1996-06-05 Von kloniertem, vitamin-d bindenden protein abgeleitete makrophagen-aktivierende faktoren
DE69635346A Expired - Lifetime DE69635346D1 (de) 1995-06-07 1996-06-05 Von kloniertem, vitamin-d bindenden protein abgeleitete makrophagen-aktivierende faktoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69635346A Expired - Lifetime DE69635346D1 (de) 1995-06-07 1996-06-05 Von kloniertem, vitamin-d bindenden protein abgeleitete makrophagen-aktivierende faktoren

Country Status (12)

Country Link
US (3) US6410269B1 (https=)
EP (3) EP1443112A3 (https=)
JP (1) JPH11511962A (https=)
CN (2) CN1510147A (https=)
AT (1) ATE307885T1 (https=)
AU (1) AU6253596A (https=)
BR (1) BR9609072A (https=)
CA (1) CA2223940A1 (https=)
DE (2) DE69635346T4 (https=)
ES (1) ES2252756T3 (https=)
NO (1) NO323155B1 (https=)
WO (1) WO1996040903A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985545A (en) * 1996-03-19 1999-11-16 Yamamoto; Nobuto Diagnostic and prognostic ELISA assays of serum α-N-acetylgalactosaminidase for AIDS
EP1280546A4 (en) * 2000-05-09 2005-02-23 Childrens Medical Center METHOD AND COMPOSITION FOR THE TREATMENT OF ANGIOGENESIS
AU2001288853A1 (en) * 2000-09-07 2002-03-22 The Brigham And Women's Hospital, Inc. Methods of detecting cancer based on prostasin
US20050009120A1 (en) * 2000-09-07 2005-01-13 The Brigham And Women's Hospital, Inc. Methods of detecting ovarian cancer based on osteopontin
CA2426154A1 (en) * 2000-11-09 2002-08-01 Northeastern Ohio Universities College Of Medicine Agents and methods for promoting bone growth
WO2002075314A2 (en) * 2000-11-30 2002-09-26 Matritech, Inc. Detection and treatment of prostate cancer
US7112408B2 (en) * 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US6806355B2 (en) 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
US7288383B2 (en) * 2003-01-15 2007-10-30 The Brigham And Women's Hospital, Inc. Eosinophil-derived neurotoxin as a marker for ovarian cancer
US8034773B2 (en) 2004-02-05 2011-10-11 Arizona Biomedical Research Commission Immunostimulatory compositions and uses thereof
US20050186577A1 (en) * 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8178649B2 (en) 2004-12-07 2012-05-15 Arizona Biomedical Research Commission Immunostimulatory compositions and uses thereof
USRE46425E1 (en) 2006-12-13 2017-06-06 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
US8496942B2 (en) 2006-12-13 2013-07-30 Susavion Biosciences, Inc. Therapeutic peptides and uses thereof
US8460697B2 (en) 2006-12-13 2013-06-11 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
US7811995B2 (en) 2006-12-13 2010-10-12 Susavion Biosciences, Inc. Therapeutic and diagnostic peptides
US7838497B2 (en) 2006-12-13 2010-11-23 Susavion Biosciences, Inc. Pro-angiogenic peptides
CA2771900A1 (en) * 2009-08-22 2011-03-10 Charles Knezevich Tumoricidal, bactericidal, or viricidal macrophage activation
JP5860401B2 (ja) 2010-09-03 2016-02-16 森田薬品工業株式会社 新規Ｇｃグロブリンガラクトース脱糖体の製造方法
CN103547280B (zh) * 2011-04-07 2017-06-09 艾弗兰纳特有限公司 用于药物组合物的巨噬细胞活化因子
EP2561879A1 (en) 2011-08-23 2013-02-27 Protea Biopharma N.V. Macrophage activating factor for use in the treatment of chronic fatigue syndrome (CFS) and CFS-related diseases and disorders
EP2819749A4 (en) * 2012-03-01 2016-03-02 Univ Columbia BIOMARKERS FOR AUTISM AND USES THEREOF
EP2687264A1 (en) 2012-07-17 2014-01-22 Protea Biopharma N.V. Macrophage Activating Factor for treatment of endometriosis
AU2014207429B2 (en) * 2013-01-18 2018-11-01 Ellis KLINE Selective glycosidase regimen for immune programming and treatment of cancer
US20160120946A1 (en) * 2013-06-09 2016-05-05 Efranat Ltd. Compositions comprising gc-macrophage activating factor and uses thereof
AT518622A1 (de) * 2016-04-21 2017-11-15 Hg Pharma Gmbh Dimerer Komplex aus selektiv deglycosyliertem Vitamin D bindenden Protein (GcMAF) und Cholecalciferol (Calciol) und Verfahren zu dessen Herstellung
WO2019117295A1 (ja) * 2017-12-15 2019-06-20 公益財団法人神戸医療産業都市推進機構 活性型ＧｃＭＡＦの製造方法
AU2021398261A1 (en) 2020-12-08 2023-07-06 Saisei Pharma Co., Ltd. Macrophage activator
CN118325844B (zh) * 2023-09-07 2025-01-03 武汉奥科博泰生物科技有限公司 识别N-乙酰-β-D-氨基葡萄糖苷酶的单克隆抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177002A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor
US5326749A (en) 1989-11-20 1994-07-05 Nobuto Yamamoto Macrophage activating factor from vitamin D binding protein
US5177001A (en) 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor
US5516657A (en) * 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
US5652352A (en) * 1994-03-31 1997-07-29 Amgen Inc. Afamin: a human serum albumin-like gene

Also Published As

Publication number Publication date
WO1996040903A1 (en) 1996-12-19
US6410269B1 (en) 2002-06-25
EP1443112A3 (en) 2004-11-03
CA2223940A1 (en) 1996-12-19
NO323155B1 (no) 2007-01-08
AU6253596A (en) 1996-12-30
EP1340815A2 (en) 2003-09-03
EP0837932A1 (en) 1998-04-29
ATE307885T1 (de) 2005-11-15
JPH11511962A (ja) 1999-10-19
DE69635346D1 (de) 2005-12-01
EP0837932B1 (en) 2005-10-26
EP1443112A2 (en) 2004-08-04
EP1340815A3 (en) 2003-09-17
CN1174097C (zh) 2004-11-03
CN1510147A (zh) 2004-07-07
CN1191567A (zh) 1998-08-26
DE69635346T2 (de) 2006-07-27
NO975771D0 (no) 1997-12-08
EP0837932A4 (en) 2001-02-28
ES2252756T3 (es) 2006-05-16
US20020055140A1 (en) 2002-05-09
US5712104A (en) 1998-01-27
BR9609072A (pt) 2000-10-24
NO975771L (no) 1998-01-30

Similar Documents

Publication Publication Date Title
DE69635346T4 (de) Von kloniertem, vitamin-d bindenden protein abgeleitete makrophagen-aktivierende faktoren
DE3880739T2 (de) Expression von menschlichem proapolipoprotein a-1.
US5641665A (en) Plasmids suitable for IL-2 expression
DE69727558T2 (de) Humanes CYR61, ein Signalmolekül der extrazellularen Matrix
DE69732129T2 (de) THERAPIE FÜR alpha GALACTOSIDASE A INSUFFIZIENZ
US5141742A (en) Vaccines against melanoma
US20100184845A1 (en) Myeloid Colony Stimulating Factor and Uses Thereof
Teumer et al. Human growth hormone in the blood of athymic mice grafted with cultures of hormone‐secreting human keratinocytes
JPS61501627A (ja) ヒトエリスロポエチンをコードするｄｎａ
KR20200100858A (ko) 수지상 세포 조성물
WO1994021808A1 (de) Verfahren zur herstellung von krebsvakzinen
Lembo et al. Inhibition of cell proliferation by the interferon-inducible 204 gene, a member of the Ifi 200 cluster
JP2002536018A (ja) グリコシル化レプチン組成物および関連する方法
DE69920405T2 (de) Verwendung des heregulins als epithelzellenwachstumsfaktor
Moullier et al. Long-term delivery of a lysosomal enzyme by genetically modified fibroblasts in dogs
JPH03195496A (ja) 成長因子
Tuszynski et al. Somatic gene transfer to the adult primate central nervous system: in vitroandin vivocharacterization of cells genetically modified to secrete nerve growth factor
CN111909246B (zh) 高效感染支持细胞的aav突变体
Yamamoto et al. A defect in inducible β‐galactosidase of B lymphocytes in the osteopetrotic (mi/mi) mouse
DE3703702C2 (de) Vakzine gegen Melanome
EP1123392B1 (de) Das gen prv-1 und dessen verwendung
DE69130818T2 (de) Chondromodulin-I-Protein
AU784155B2 (en) Myeloid colony stimulating factor and uses thereof
AU1458200A (en) A myeloid precursor cell useful for gene therapy and for modulation of immune responses
WO1999011796A1 (en) Hnk-1 sulfotransferase and methods of use therefor